A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

PHASE2CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

February 16, 2016

Primary Completion Date

July 17, 2018

Study Completion Date

July 17, 2018

Conditions
Systemic Lupus Erythematosus
Interventions
BIOLOGICAL

XmAb5871

BIOLOGICAL

Placebo to match XmAb5871

Trial Locations (23)

10016

NYU Langone Medical Center, New York

10021

Hospital for Special Surgery, New York

10461

Columbia University Medical Center, The Bronx

11030

Feinstein Institute for Medical Research, Manhasset

11203

Suny Downstate Medical Center, Brooklyn

16635

Altoona Center for Clinical Research, Duncansville

20010

MedStar Washington Hospital Center, Washington D.C.

27517

CTRC University of North Carolina at Chapel Hill, Chapel Hill

28210

DJL Clinical Research, Charlotte

30309

Piedmont Atlanta Rheumatology, Atlanta

30322

Emory University School of Medicine, Atlanta

33309

Center For Rheumatology, Fort Lauderdale

44130

Paramount Medical Research and Consulting LLC, Cleveland

48910

Joshua P June, DO, Lansing

60611

Northwestern University, Chicago

60637

University of Chicago, Chicago

63110

Washington University, St Louis

73103

Arthritis & Rheumatology Center of Oklahoma, PLLC, Oklahoma City

74104

Oklahoma Center for Arthritis Therapy & Research, Tulsa

92037

UC San Diego, La Jolla

92354

Loma Linda University, Loma Linda

94578

East Bay Rheumatology Medical Group, San Leandro

06250

Yale University School of Medicine, New Haven

Sponsors
All Listed Sponsors
collaborator

PPD Development, LP

INDUSTRY

collaborator

ICON plc

INDUSTRY

lead

Xencor, Inc.

INDUSTRY